Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (Part II) Clear all

Conditions: Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions: Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Head and Neck Cancer
Interventions: Everolimus, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Interventions: Nintedanib and AML induction; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: New Haven, Connecticut • Nashville, Tennessee

Conditions: Sickle Cell Disease
Interventions: ITU512, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Healthy Volunteers
Interventions: Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3, Blinded Study Medication - Condition 4, Blinded Study Medication - Condition 5, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Controls, Alcohol Use Disorder
Interventions: Placebo, Oxytocin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions: Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT); Biological · Drug · Other
Lead sponsor: Rima Rachid; Other
Eligibility: 12 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: Hemophilic Arthropathy
Interventions: TRM-201 (Rofecoxib), Placebo; Drug
Lead sponsor: Tremeau Pharmceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 15 more

Conditions: Digestive Health, Quality of Life
Interventions: Fermented dairy protein with prebiotic fiber supplement, Control placebo; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Myelodysplastic Syndromes
Interventions: Oral Azacitidine, Placebo for Oral Azacitidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Miami, Florida • Tamarac, Florida • East Syracuse, New York + 3 more

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more

Conditions: Rheumatoid Arthritis
Interventions: Anti-TNF-alpha, Methotrexate, Placebo, RO7123520; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more

Conditions: Advanced Malignant Neoplasm, Dermatologic Complication
Interventions: Doxycycline, Management of Therapy Complications, Placebo, Questionnaire Administration, Spironolactone, Sunscreen, Therapeutic Hydrocortisone; Drug · Procedure · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more

Conditions: Hepatitis C
Interventions: INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anaheim, California • La Jolla, California • San Francisco, California + 3 more

Conditions: Covid19
Interventions: Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more

Conditions: Rheumatoid Arthritis
Interventions: SAR441566, Placebo, Ciprofloxacin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Search by objective public record fields.

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Measuring Acute Drug Demand in Humans II

Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566